Psyrin

Psyrin is a London-based mental health technology company founded in 2024 to address a systemic crisis in psychiatric care. The founding team — Dr. Edwin Wong (CEO), Dr. Julianna Olah (CTO), and Dr. Raheem Chaudhry (COO) — recognised that traditional mental health assessment is profoundly limited: it depends on individual clinician expertise, is highly subjective, is time-intensive, and creates bottlenecks where the average wait for a neurodivergent assessment in the UK can exceed 500 weeks. The company's goal is to build an objective, scalable, biomarker-based standard for mental health diagnostics.

Psyrin's flagship product, Simon AI, uses voice biomarkers to screen for neurodivergent traits including ADHD and autism. By analysing over 200 distinct vocal characteristics — from speech rhythm, tone, and volume to complex mathematical transformations of voice patterns — Simon AI can provide individuals with data-driven insights about their mental health in around 60 seconds. The platform has demonstrated accuracy exceeding 80% in research studies for identifying ADHD and autism, and is already being used in US clinics to support assessments for schizophrenia, bipolar disorder, and depressive disorder. Simon AI is not a replacement for clinical diagnosis but offers a faster, more accessible and objective first step in understanding neurodivergent traits.

Psyrin raised $1 million in pre-seed funding in 2024, led by 2048 Ventures with participation from Concept Ventures and Space Cadet Ventures. The company's longer-term vision extends beyond consumer screening to supporting clinicians in monitoring serious mental illness and enabling earlier intervention in conditions that currently go undetected until they become acute.